Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DME6UOM)

Drug Name
4-Methyl-pyridine Drug Info
Synonyms
4-METHYLPYRIDINE; 4-Picoline; 108-89-4; Pyridine, 4-methyl-; p-Picoline; gamma-Picoline; p-Methylpyridine; 4-methyl-pyridine; gamma-Methylpyridine; Ba 35846; UNII-TJD6V9SSO7; .gamma.-Picoline; NSC 18252; 4-Mepy; CCRIS 1723; .gamma.-Methylpyridine; HSDB 5386; EINECS 203-626-4; TJD6V9SSO7; AI3-24111; CHEBI:32547; FKNQCJSGGFJEIZ-UHFFFAOYSA-N; 4-Picoline, 99%; DSSTox_CID_1892; DSSTox_RID_76389; DSSTox_GSID_21892; 4-methyl pyridine; CAS-108-89-4; gamma-picolin; 4-Pyridylmethyl; 4-pi-coline; para-Methylpyridine; Methyl, 4-pyridinyl-; 4-Picoline
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
7963
ChEBI ID
CHEBI:32547
CAS Number
CAS 108-89-4
TTD Drug ID
DME6UOM

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Thromboxane-A synthase (TBXAS1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PYRIDINE DMF8CJ9 N. A. N. A. Phase 4 [1]
NM-702 DMDJLY9 Angina pectoris BA40 Phase 3 [2]
E-6700 DMUWJI4 Asthma CA23 Phase 2 [3]
FK-070 DMJSD5W Angina pectoris BA40 Phase 2 [4]
EV-077 DM1FCDH Type-2 diabetes 5A11 Phase 2 [5]
G-619 DM3H6YC Thrombosis DB61-GB90 Phase 1 [6]
NV-52 DM0UOA9 Inflammatory bowel disease DD72 Phase 1 [7]
Satigrel DM4LSJ2 Thrombosis DB61-GB90 Discontinued in Preregistration [8]
MILACAINIDE TARTRATE DMJLNUD Cardiac arrhythmias BC9Z Discontinued in Phase 2 [9]
Imitrodast DMQ2ULV Asthma CA23 Discontinued in Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Thromboxane-A synthase (TBXAS1) TTKNWZ4 THAS_HUMAN Inhibitor [1]

References

1 Highly selective inhibitors of thromboxane synthetase. 2. Pyridine derivatives. J Med Chem. 1981 Oct;24(10):1149-55.
2 The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol. 2006 Dec 19;48(12):2539-45.
3 Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase. J Med Chem. 1996 Aug 2;39(16):3148-57.
4 Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers. J Pharm Pharmacol. 1996 Apr;48(4):380-5.
5 Company report (Pharmaceuticalintelligence)
6 G 619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, inhibits tumor necrosis factor-alpha biosynthesis. Eur J Pharmacol. 1995 Nov 3;286(1):31-9.
7 Phase Ib single- and multiple-dose pharmacokinetic study of oral NV-52 in healthy volunteers. Drugs R D. 2008;9(3):159-66.
8 Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities. Biol Pharm Bull. 1996 Jun;19(6):828-33.
9 Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory activity. J Pharmacol Exp Ther. 1996 Nov;279(2):877-83.
10 RS-5186, a novel thromboxane synthetase inhibitor with a potent and extended duration of action. Thromb Res. 1988 Sep 1;51(5):507-20.